The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 5.66 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.62 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as BIOGEN INC. reports it. History and quarterly detail are in the app.
- Product revenue, net$7.1B
- Subtotal: Multiple Sclerosis$4.0B
- Subtotal: Rare Disease$2.2B
- Revenue from anti-CD20 therapeutic programs$1.9B
- Total Fumarate$1.4B
Leadership changes
From BIOGEN INC.'s own filings, the day they're filed.
- Caroline Dorsa · Directors · departureeff. 2026-02-11
- Sean Godbout · President · appointmenteff. 2025-03-01
- Robin Kramer · principal accounting officer as of the · appointmenteff. 2025-03-01
Latest filings
- 8-K · Company announcement2026-06-10
- 8-K · Company announcement2026-05-14
- 8-K · Company announcement2026-04-29
- 10-Q · Quarterly report2026-04-29
- DEF 14A · Annual proxy (pay & governance)2026-04-28
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BIOGEN INC., every answer cited🔒
- The Intelligence Brief — added when BIOGEN INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.